medicare coverage of glp 1 cover Medicare could be changing its stance on covering weight loss drugs like Nearly Four Million Medicare Beneficiaries

The heterogeneity and complexity of these disorders have proved to be major challenges for drug development

Understanding the molecular processes involved in the development of diabetes and its debilitating vascular complications might bring up more effective and specific clinical therapies

Phase 3 data showed 18.6% weight loss at 46 weeks

The changes are likely to last

and projects to the DMH to control glucose metabolism [49]

In 2024 the Food and Drug Administration added cardiovascular risk as a reason to be prescribed the GLP-1 drug Wegovy, grounded in results from a major trial that showed fewer heart attacks, strokes, and cardiovascular deaths in adults with obesity or overweight and established heart disease